LONDON (Reuters) - Glitches and delays in the manufacturing of coronavirus vaccines are inevitable given the speed at which they have been developed, AstraZeneca CEO Pascal Soriot told a news briefing on Friday.
Soriot said he would not comment on a dispute with the European Union over supplies, seeking to focus instead on the regulatory approval for the vaccine granted on Friday by the European Medicines Agency.
Editing by Keith Weir; Editing by Hugh Lawson
Our Standards: The Thomson Reuters Trust Principles.